These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36233514)

  • 21. Ocular surface disease associated with immune checkpoint inhibitor therapy.
    Park RB; Jain S; Han H; Park J
    Ocul Surf; 2021 Apr; 20():115-129. PubMed ID: 33610743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
    Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
    Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
    Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
    Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
    Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ophthalmic complications of immune checkpoint inhibitors.
    Wladis EJ; Kambam ML
    Orbit; 2022 Feb; 41(1):28-33. PubMed ID: 33386059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
    Kawashima S; Joachim K; Abdelrahim M; Abudayyeh A; Jhaveri KD; Murakami N
    Korean J Transplant; 2022 Jun; 36(2):82-98. PubMed ID: 35919193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocular and orbital side-effects of checkpoint inhibitors: a review article.
    Antoun J; Titah C; Cochereau I
    Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular surface complications following biological therapy for cancer.
    Ma KS; Tsai PF; Hsieh TY; Chodosh J
    Front Toxicol; 2023; 5():1137637. PubMed ID: 37424746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer.
    Calabrese LH; Caporali R; Blank CU; Kirk AD
    J Autoimmun; 2020 Dec; 115():102546. PubMed ID: 32980229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wu X
    J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.
    Wassmer CH; El Hajji S; Papazarkadas X; Compagnon P; Tabrizian P; Lacotte S; Toso C
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of Resistance to Checkpoint Inhibitors.
    Tran L; Theodorescu D
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular side effects of checkpoint inhibitors.
    Alba-Linero C; Alba E
    Surv Ophthalmol; 2021; 66(6):951-959. PubMed ID: 33440195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study.
    Nikita N; Banks J; Keith SW; Song A; Johnson JM; Wilson M; Sharma S; Lu-Yao G
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-target combinatory strategy to overcome tumor immune escape.
    Yu Y
    Front Med; 2022 Apr; 16(2):208-215. PubMed ID: 35377102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review.
    Rossi E; Schinzari G; Maiorano BA; Esposito I; Acampora A; Romagnoli J; Stefani AD; Regno LD; Lancellotta V; Fionda B; Tagliaferri L; Peris K; Tortora G
    Immunotherapy; 2022 Jan; 14(1):65-75. PubMed ID: 34751039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.